Cochrane Library: Erythropoiesis-stimulating agents for anemia
Anemia affects nearly all adults with advanced kidney disease and is linked to fatigue, breathlessness, impaired quality of life and physical function, and shorter survival. ESA treatment aims to improve anemia-related symptoms and minimize treatment-related cardiovascular events. Several ESA classes are available for anemia treatment (epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta as well as biosimilar ESAs) but whether these drugs have differing benefits and harms is uncertain. This Cochrane review directly compares available ESAs for treatment of anemia among adults with chronic kidney disease.
Suetonia is a nephrologist based at the University of Otago, Christchurch in New Zealand, and who trained in New Zealand and the USA. She is an Editor for Cochrane Kidney and Transplant.
Giovanni is a nephrologist based at the University of Bari in Italy, who also trained at the Sydney School of Public Health, Australia. He is an Editor for Cochrane Kidney and Transplant and the journal Nephrology, Dialysis and Transplantation.
Copyright© 2015 Cochrane Kidney and Transplant. Published by John Wiley & Sons, Ltd.